Joshua K. Sabari, MD

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.

Joshua K. Sabari, MD, discusses the role of concurrent plasma- and tissue-based molecular testing in lung cancer.

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the management of immune-related adverse events (irAEs) in patients with lung cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses the role of immunotherapy in the treatment of patients with small cell lung cancer.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in non–small cell lung cancer.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.